Company: BOLT
Filing Date: 2025-04-15
Form Type: DEF 14A
Source: 0000950170-25-054294
Chunk: 28

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-04-15
Form: DEF 14A
Chunk 28
---
 and was granted an option to purchase 50,000 shares of common stock with an exercise price of $0.6798 per share which will vest monthly as to 1/36th of such shares, subject to Dr. Dupont’s continuous service with us on each applicable vesting date. Dr. Dupont was granted an additional option to purchase 16,984

<div align='center'>17</div>

shares of common stock with an exercise price of $0.6798 per share which will vest on the date immediately preceding the date of the 2025 Annual Meeting of Stockholders. (9) Dr. Onetto is compensated at a rate of $10,000 annually to chair our Development Advisory Board. The Development Advisory Board provides strategic recommendations from a scientific, clinical, and regulatory perspective regarding our research and development programs. Non-Employee Director Compensation Policy We adopted a non-employee director compensation policy pursuant to which our non-employee directors are eligible to receive cash and equity compensation for service on our Board and committees of our Board. Each non-employee director is entitled to receive an annual cash retainer of $35,000 for serving on our Board. The chairperson of our Board is entitled to a cash retainer of $65,000 in lieu of the annual retainer received by other non-employee directors. The chairperson and members of the following three committees of our Board are entitled to the following additional annual cash retainers:

| Board Committee                               |     | Chairperson Fee ($) |        |     | Member Fee ($) |       |
| Audit Committee                               |     |                     | 15,000 |     |                | 7,500 |
| Compensation Committee                        |     |                     | 10,000 |     |                | 5,000 |
| Nominating and Corporate Governance Committee |     |                     |  8,000 |     |                | 4,000 |
| Research and Development Committee (1)        |     |                     | 10,000 |     |                | 5,000 |

_________________ (1) The research and development committee was dissolved in June 2024. All annual cash retainers are payable in equal quarterly installments in arrears, on the last day of each fiscal quarter for which the service occurred, prorated based on the number of days served in the applicable fiscal quarter. Each new non-employee director who joins our Board will receive an option to purchase 50,000 shares of our common stock under our 202